A Psoriasiform Reaction on a TNF Inhibitor: Continue Through It or Switch Mechanism
The same drug that finally controlled his joints has, four years in, triggered a skin reaction that TNF inhibition itself is known to cause — a paradox that doesn't resolve cleanly toward either stopping or continuing.
Victor H., a 57-year-old man, has worked construction for over thirty years and currently runs the site for a mid-rise apartment building going up downtown, a job that keeps him on his feet and, until recently, hadn't been slowed by his joints in years. Adalimumab combined with methotrexate brought his rheumatoid arthritis into sustained remission four years ago and has held it there since. Over the past two months, though, he's developed new pustular, scaling plaques across both palms and soles, biopsy-confirmed as psoriasiform dermatitis, with a clear temporal link to his adalimumab and no personal or family history of psoriasis before this.
The reaction is a recognized, if uncommon, paradox of the exact mechanism that has kept his joints quiet: TNF-alpha inhibition, for reasons not fully understood, can trigger new-onset psoriasiform skin disease in a genuine subset of patients, a class effect described across all the TNF inhibitors rather than one specific to adalimumab, and one that typically surfaces years into an otherwise unremarkable course rather than early, which fits his four-year timeline. A decade-long Cleveland Clinic cohort of TNF-inhibitor-induced psoriasis put numbers to what happens next, and they cut in both directions. Switching to a different TNF inhibitor left the eruption persisting or recurring in 64% of patients — evidence pointing at the mechanism rather than the individual molecule. But topical treatment alone improved or resolved the reaction in 63.5%, with palmoplantar pustulosis among the most commonly represented patterns, which is a real argument for trying the conservative step before abandoning a regimen that works. One option that might seem to solve both problems at once, an IL-17 inhibitor, doesn't apply here despite treating psoriasis effectively: the NURTURE trial compared secukinumab against abatacept in RA after TNF inhibitor failure and found no incremental benefit, and a later phase 3 study by Dokoupilova and colleagues failed to beat placebo on ACR20 at 24 weeks. Development of the drug for RA was abandoned on those results, so it isn't a genuine option for his joint disease at all. His biopsy findings — sterile, neutrophil-rich pustules under the microscope — look identical to idiopathic palmoplantar pustulosis on their own, which is exactly what makes the paradoxical pattern hard to separate from a coincidental new skin disease without the clear temporal link both his dermatologist and rheumatologist noticed independently.
A reaction to the drug that's working
I'd move away from TNF inhibition as a mechanism entirely rather than try a different TNF inhibitor. Paradoxical psoriasiform reactions are a recognized class effect of TNF blockade, and the Cleveland Clinic cohort found that switching to another TNF inhibitor left the eruption persisting or recurring in 64% of patients — which points to the mechanism, not the specific molecule, as the actual driver.
I hear that, and I agree the class-effect data are real. But he's been in sustained remission for four years on this exact regimen, which is a genuine, demonstrated result I'd be reluctant to give up before trying the more conservative step first: the same Cleveland Clinic series found topicals alone improved or resolved the eruption in 63.5% of patients with the TNF inhibitor continued, with a switch reserved for reactions that don't settle.
I want to be honest that the tempting-looking third option — an IL-17 inhibitor, which treats psoriasis directly — isn't actually available to us here. NURTURE found secukinumab gave no incremental benefit over abatacept in RA after TNF failure, and Dokoupilova's later phase 3 study didn't beat placebo on ACR20 — development for RA was dropped. So it isn't a genuine option for his joint disease regardless of how well it might address the skin.
So the real choice is between your position and mine, not a third path that solves both problems at once. I'd propose trying topical therapy with close dermatology follow-up for a defined window, with an explicit plan to switch to a non-TNF mechanism if it doesn't clear.
Agreed: continue adalimumab with high-potency topical corticosteroid therapy and close dermatology follow-up for eight weeks, with an explicit plan to switch to abatacept, not an IL-17 inhibitor, if the skin reaction hasn't meaningfully improved by then.
Not agreed: whether trying the conservative route at all was the right call given the dermatologist's reading of the class-effect literature. The dermatologist's position remains that a mechanism switch gives the better chance of actually resolving the skin reaction; the rheumatologist's position is that four years of joint remission earned a defined trial of the more conservative step first. The eight-week checkpoint was set specifically so this disagreement doesn't have to be resolved before acting.